CARY, N.C., Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of ...
Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q3 2025 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now ...
Detailed price information for Heron Therapeutics (HRTX-Q) from The Globe and Mail including charting and trades.
Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $-0.01333. Operator: Good day, and thank you for standing by. Welcome to the Heron Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback